Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

First-in-class phosphate absorption inhibitor approved by FDA

4
SHARES

A first-in-class treatment with a differentiated mechanism of action has been approved to reduce serum phosphorus in chronic kidney disease (CKD) in individuals for which phosphate binders are not suitable.

XPHOZAH - first-in-class phosphate absorption inhibitor approved by FDA

The US Food and Drug Administration (FDA) has approved XPHOZAH ® (tenapanor), the first and only phosphate absorption inhibitor.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Ardelyx’s first-in-class oral treatment is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant to phosphate binder therapy.

About the approved phosphate absorption inhibitor

XPHOZAH acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). As a result, it reduces phosphate absorption through the paracellular pathway, the primary pathway of phosphate absorption, according to Ardelyx.

“The approval of XPHOZAH is an important milestone for patients on dialysis… it represents a new mechanism and new option for patients who, despite treatment with phosphate binders, continue to have elevated phosphorus,” stated Mike Raab, President and Chief Executive Officer of Ardelyx.

Clinical evidence supporting FDA-approval

Approval of the phosphate absorption inhibitor XPHOZAH was based on data from 1,000 patients in three Phase III clinical trials (PHREEDOM, BLOCK and AMPLIFY) evaluating the efficacy and safety of XPHOZAH. It was investigated both as monotherapy and in combination with phosphate binder therapy. Overall, the data showed that XPHOZAH significantly reduced elevated serum phosphorus in patients receiving maintenance hemodialysis.

However, in the trials, the only observed adverse reaction for the treatment was diarrhoea. This reportedly occurred in 43 to 53 percent of patients; in at least five percent of XPHOZAH-treated patients with chronic kidney disease on dialysis across trials. Most XPHOZAH-treated patients experienced mild-to-moderate reactions that resolved over time, or with dose reduction.

Further to the three Phase III trials for XPHOZAH, Ardelyx also declared that it has completed two open-label clinical trials (OPTIMIZE and NORMALIZE) to evaluate different options for integrating the treatment into clinical practice.

XPHOZAH is expected to be available to eligible patients in the US in November 2023.

Share via
Share via